Loading...
•
Dec 31, 2024
AbbVie Q4 2024 Earnings Report
AbbVie's Q4 2024 financial results were reported, showing revenue increase and mixed performance across different portfolios.
Key Takeaways
AbbVie reported a 5.6% increase in net revenues for Q4 2024, reaching $15.102 billion. The company's adjusted diluted EPS was $2.16, which includes an unfavorable impact of $0.88 related to acquired IPR&D and milestones expense. While some portfolios like Neuroscience and Oncology experienced growth, others like Aesthetics saw a decrease. The company provides 2025 adjusted diluted EPS guidance range of $12.12 to $12.32.
Worldwide net revenues increased by 5.6% to $15.102 billion.
Adjusted diluted EPS was $2.16, impacted by acquired IPR&D and milestones expense.
Immunology portfolio net revenues increased by 4.9% to $7.294 billion, driven by Skyrizi and Rinvoq.
Neuroscience portfolio net revenues increased by 19.8% to $2.509 billion, led by Botox Therapeutic and Vraylar.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
AbbVie provided its adjusted diluted EPS guidance for the full-year 2025 of $12.12 to $12.32. The company reaffirms expectations for a high single-digit compound annual revenue growth rate through 2029. AbbVie is raising its long-term outlook for Skyrizi and Rinvoq revenues and now expects combined Skyrizi and Rinvoq 2027 revenues of more than $31 billion. AbbVie is also updating its outlook for aesthetics revenues and now expects a high single-digit compound annual revenue growth rate for aesthetics through 2029.
Positive Outlook
- Adjusted diluted EPS guidance for full-year 2025 is $12.12 to $12.32.
- Reaffirms expectations for high single-digit compound annual revenue growth rate through 2029.
- Combined Skyrizi and Rinvoq 2027 revenues are expected to be more than $31 billion.
- Skyrizi revenues of more than $20 billion in 2027 are expected.
- Aesthetics revenues are expected to have a high single-digit compound annual revenue growth rate through 2029.
Challenges Ahead
- 2025 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones.
- Long-term guidance assumes 2024 as the base year in the compound annual growth rate calculation.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...